Xencor, Inc Amortization of Debt Issuance Costs
Xencor, Inc (XNCR) reported Amortization of Debt Issuance Costs of $1.21 million for the 12-month period ending 2013-12-31, per its 10-K filed 2016-03-08.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AmortizationOfFinancingCosts · last filed 2016-03-08
- Xencor, Inc amortization of debt issuance costs for fiscal 2013 was $1.21M, a 50.69% decline from fiscal 2012.
- Xencor, Inc amortization of debt issuance costs for fiscal 2012 was $2.46M.
| Period end | Amortization of Debt Issuance Costs 12 month |
|---|---|
| 2013-12-31 | $1.21M 10-K · filed 2016-03-08 |
| 2012-12-31 | $2.46M 10-K · filed 2015-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |